Pediatrix Medical Group, Inc. $MD Position Cut by Brandes Investment Partners LP

Brandes Investment Partners LP lowered its holdings in shares of Pediatrix Medical Group, Inc. (NYSE:MD) by 18.1% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 565,212 shares of the company’s stock after selling 124,946 shares during the period. Brandes Investment Partners LP owned approximately 0.65% of Pediatrix Medical Group worth $8,111,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in MD. LPL Financial LLC increased its holdings in shares of Pediatrix Medical Group by 55.5% during the first quarter. LPL Financial LLC now owns 144,318 shares of the company’s stock valued at $2,091,000 after purchasing an additional 51,490 shares during the period. Mackenzie Financial Corp grew its position in Pediatrix Medical Group by 82.7% in the 1st quarter. Mackenzie Financial Corp now owns 38,399 shares of the company’s stock valued at $556,000 after buying an additional 17,376 shares in the last quarter. XTX Topco Ltd increased its stake in Pediatrix Medical Group by 246.5% during the 1st quarter. XTX Topco Ltd now owns 44,752 shares of the company’s stock valued at $648,000 after buying an additional 31,835 shares during the period. Natixis Advisors LLC increased its stake in Pediatrix Medical Group by 8.1% during the 1st quarter. Natixis Advisors LLC now owns 19,156 shares of the company’s stock valued at $278,000 after buying an additional 1,435 shares during the period. Finally, Empirical Financial Services LLC d.b.a. Empirical Wealth Management bought a new stake in shares of Pediatrix Medical Group during the 1st quarter worth about $159,000. Institutional investors and hedge funds own 97.71% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on MD shares. Zacks Research upgraded shares of Pediatrix Medical Group from a “hold” rating to a “strong-buy” rating in a report on Friday, November 21st. UBS Group upped their target price on Pediatrix Medical Group from $16.50 to $23.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 5th. Truist Financial lifted their price target on Pediatrix Medical Group from $17.00 to $24.00 and gave the company a “hold” rating in a research report on Monday, November 10th. Leerink Partners boosted their price objective on Pediatrix Medical Group from $14.50 to $17.00 and gave the stock a “market perform” rating in a research note on Friday, September 5th. Finally, Wall Street Zen raised Pediatrix Medical Group from a “buy” rating to a “strong-buy” rating in a research note on Saturday, October 4th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $21.00.

Insider Activity at Pediatrix Medical Group

In other news, Director Michael A. Rucker sold 10,478 shares of Pediatrix Medical Group stock in a transaction on Monday, November 17th. The stock was sold at an average price of $23.00, for a total transaction of $240,994.00. Following the transaction, the director owned 59,101 shares in the company, valued at approximately $1,359,323. The trade was a 15.06% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Laura A. Linynsky sold 10,000 shares of the stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $21.65, for a total value of $216,500.00. Following the completion of the sale, the director directly owned 32,232 shares of the company’s stock, valued at approximately $697,822.80. This represents a 23.68% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.90% of the stock is currently owned by corporate insiders.

Pediatrix Medical Group Trading Down 1.2%

Shares of NYSE MD opened at $23.79 on Wednesday. The company has a quick ratio of 1.80, a current ratio of 1.80 and a debt-to-equity ratio of 0.70. Pediatrix Medical Group, Inc. has a 12 month low of $11.84 and a 12 month high of $24.99. The company has a market cap of $2.04 billion, a price-to-earnings ratio of 18.44 and a beta of 0.76. The business has a fifty day simple moving average of $19.56 and a 200-day simple moving average of $16.32.

Pediatrix Medical Group (NYSE:MD) last posted its quarterly earnings data on Monday, November 3rd. The company reported $0.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.46 by $0.21. Pediatrix Medical Group had a return on equity of 18.94% and a net margin of 5.66%.The firm had revenue of $492.88 million for the quarter, compared to the consensus estimate of $476.45 million. During the same quarter in the previous year, the company earned $0.44 EPS. The business’s revenue for the quarter was down 3.6% compared to the same quarter last year. Sell-side analysts predict that Pediatrix Medical Group, Inc. will post 1.38 EPS for the current year.

Pediatrix Medical Group Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.